A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy

Ohana,Gil; Cohen,Shira; Rath‑Wolfson,Lea; Fishman,Pnina

doi:10.3892/mmr.2016.5746

A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy

Authors:
- Gil Ohana
- Shira Cohen
- Lea Rath‑Wolfson
- Pnina Fishman
View Affiliations

Affiliations: Department of Surgery A/B, Rabin Medical Center, Campus Golda, Sackler Faculty of Medicine Tel‑Aviv University, Petah Tikva 49100, Israel, Can‑Fite BioPharma, Ltd., Kiryat‑Matalon, Petah Tikva 49170, Israel, Department of Pathology, Rabin Medical Center, Campus Golda, Sackler Faculty of Medicine Tel‑Aviv University, Petah Tikva 49100, Israel
Published online on: September 19, 2016 https://doi.org/10.3892/mmr.2016.5746
Pages: 4335-4341

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ischemia/reperfusion (IR) injury during clinical hepatic procedures is characterized by inflammatory conditions and the apoptosis of hepatocytes. Nuclear factor‑κB (NF‑κB), nitric oxide and the expression levels of inflammatory cytokines, tumor necrosis factor‑α and interleukin‑1 were observed to increase following IR and mediate the inflammatory response in the liver. CF102 is a highly selective A3 adenosine receptor (A3AR) agonist, and has been identified to induce an anti‑inflammatory and protective effect on the liver via the downregulation of the NF‑κB signaling pathway. The present study aimed to determine the effect of CF102 on protecting the liver against IR injury. The potential protective effect of CF102 (100 µg/kg) was assessed using an IR injury model on 70% of the liver of Wistar rats, which was induced by clamping the hepatic vasculature for 30 min. The regenerative effect of CF102 was assessed by the partial hepatectomy of 70% of the liver during 10 min of IR. CF102 reduced the levels of liver enzymes following IR injury. A higher regeneration rate in the CF102 treatment group was observed compared with the control group, suggesting that CF102 had a positive effect on the proliferation of hepatocytes following hepatectomy. CF102 had a protective effect on the liver of Wistar rats subsequent to IR injury during hepatectomy. This may be due to an anti‑inflammatory and anti‑apoptotic effect mediated by the A3AR.

View Figures

View References

1	Lentsch AB, Atsushi K, Yoshidome H, MacMasters KM and Edwards MJ: Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology. 32:169–173. 2000. View Article : Google Scholar : PubMed/NCBI
2	Semenza GL: HIF-1: Mediator of physiological and pathophysiological response to hypoxia. J Appl Physiol (1985). 88:1474–1480. 2000.PubMed/NCBI
3	Li C and Jackson RM: Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol. 282:C227–C241. 2002. View Article : Google Scholar : PubMed/NCBI
4	Jaeschke H: Mechanisms of reperfusion injury after warm ischemia of the liver. J Hepatobiliary Pancreat Surg. 5:402–408. 1998. View Article : Google Scholar : PubMed/NCBI
5	Okuaki Y, Miyazaki H, Zeniya M, Ishikawa T, Ohkawa Y, Teuno S, Sakaguchi M, Hara M, Takahashi H and Toda G: Splenectomy-reduced hepatic injury induced by ischemia/reperfusion in the rat. Liver. 16:188–194. 1996. View Article : Google Scholar : PubMed/NCBI
6	Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L and Ehgelhardt JF: CD4(⁺) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest. 100:279–289. 1997. View Article : Google Scholar : PubMed/NCBI
7	Liu P, McGuire GM, Fischer MA, Farhood A, Smith CW and Jaeschke H: Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. Shock. 3:56–62. 1995. View Article : Google Scholar : PubMed/NCBI
8	Gao W, Bentely RC, Madden JF and Clavien PA: Apoptosis of sinusoidal endothelial cells is a critical mechanism of prevention of injury in rat liver transplantation. Hepatology. 27:1652–1660. 1998. View Article : Google Scholar : PubMed/NCBI
9	Cursio R, Gugenheim J, Ricci JE, Crenesse D, Rostagno P, Maulon L, Saint-Paul MC, Ferrua B and Auberger AP: A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB J. 13:253–261. 1999.PubMed/NCBI
10	Kohli V, Selzner M, Madden JF, Bentley RC and Clavien PA: Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver. Transplantation. 67:1099–1105. 1999. View Article : Google Scholar : PubMed/NCBI
11	Murry CE, Jenning RB and Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation. 74:1124–1136. 1986. View Article : Google Scholar : PubMed/NCBI
12	Teoh NC and Farrell GC: Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol. 18:891–902. 2003. View Article : Google Scholar : PubMed/NCBI
13	Peralta C, Closa D, Xaus C, Gelpi E, Roselló-Catafau J and Hotter G: Hepatic preconditioning in rats is defined by a balance of adenosine and xanthine. Hepatology. 28:768–773. 1998. View Article : Google Scholar : PubMed/NCBI
14	Teoh N, Pena A Dela and Farrel G: Hepatic ischemia preconditioning in mice is associated with activation of NF-kappaB, p38 kinase, and cell cycle entry. Hepatology. 36:94–102. 2002. View Article : Google Scholar : PubMed/NCBI
15	Gross ER, Hsu AK and Gross GJ: Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res. 94:960–966. 2004. View Article : Google Scholar : PubMed/NCBI
16	Vaughn BP, Robson SC and Longhi MS: Purinergic signaling in liver disease. Dig Dis. 32:516–24. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sun X, Imai M, Nowak-Machen M, Guckelberger O, Enjyoj K, Wu Y, Khalpey Z, Berberat P, Munasinghe J and Robson SC: Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia. Purinergic Signal. 7:427–434. 2011. View Article : Google Scholar : PubMed/NCBI
18	Black RG Jr, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R and Auchampach JA: Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res. 91:165–172. 2002. View Article : Google Scholar : PubMed/NCBI
19	Cross HR, Murphy E, Black RG, Auchampach J and Steenbergen C: Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol. 283:H1562–H1568. 2002. View Article : Google Scholar : PubMed/NCBI
20	Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV and Jacobson KA: A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care. 10:R652006. View Article : Google Scholar : PubMed/NCBI
21	Chen GJ, Harvey BK, Shen H, Chou J, Victor A and Wang Y: Activation of A3 adenosine receptors reduces ischemic brain injury in rodents. J Neurosci Res. 84:1848–1855. 2006. View Article : Google Scholar : PubMed/NCBI
22	Borea PA, Varani K, Vincenzi F, Baraldi PG, Tabrizi MA, Merighi S and Gessi S: The A3 adenosine receptor: History and perspectives. Pharmacol Rev. 67:74–102. 2015. View Article : Google Scholar : PubMed/NCBI
23	Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A and Madi L: An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene. 23:2465–2471. 2004. View Article : Google Scholar : PubMed/NCBI
24	Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L and Khalili K: Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene. 21:4060–4064. 2002. View Article : Google Scholar : PubMed/NCBI
25	Hanada T and Yoshimura A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13:413–421. 2002. View Article : Google Scholar : PubMed/NCBI
26	Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S and Baharav E: The PI3K-NF-kappa B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther. 8:R332006. View Article : Google Scholar : PubMed/NCBI
27	Shackelford RE, Alford BP, Xue Y, Thai SF, Adams DO and Pizzo S: Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol. 52:421–429. 1997.PubMed/NCBI
28	Ohana G, Bar-Yehuda S, Barer F and Fishman P: Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. J Cell Physiol. 186:19–23. 2001. View Article : Google Scholar : PubMed/NCBI
29	Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA and Fishman P: CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 226:2438–2447. 2011. View Article : Google Scholar : PubMed/NCBI
30	Higgins G and Anderson R: Experimental pathology of the liver: restoration of the liver of the white rat following partial surgical removal. Arch Pathol. 12:186–202. 1931.
31	Kogure K, Zhang YQ, Shibata H and Kojima I: Immediate onset of DNA synthesis in remnant rat liver after 90% hepatectomy by administration of follistatin. J Hepatol. 29:977–984. 1998. View Article : Google Scholar : PubMed/NCBI
32	Selzner M and Clavien PA: Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway. Hepatology. 31:35–42. 2000. View Article : Google Scholar : PubMed/NCBI
33	Auchampach JA, Ge ZD, Wan TC, Moore J and Gross GJ: A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol. 285:H607–H613. 2003. View Article : Google Scholar : PubMed/NCBI
34	Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS and Pathak S: The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res. 269:230–236. 2001. View Article : Google Scholar : PubMed/NCBI
35	Maddock HL, Mocanu MM and Yellon DM: Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol. 283:H1307–H1313. 2002. View Article : Google Scholar : PubMed/NCBI
36	Rivo J, Zeira E, Galun E and Matot I: Activation of A3 adenosine receptors provides lung protection against ischemia reperfusion injury associated with reduction in apoptosis. Am J Transplant. 4:1941–1948. 2004. View Article : Google Scholar : PubMed/NCBI
37	Jacobson KA, Hoffmann C, Cattabeni F and Abbracchio MP: Adenosine-induced cell death: Evidence for receptor-mediated signaling. Apoptosis. 4:197–211. 1999. View Article : Google Scholar : PubMed/NCBI
38	Abbracchio MP, Ceruti S, Brambilla R, Franceschi C, Malorni W, Jacobson KA, von Lubitz DK and Cattabeni F: Modulation of apoptsis by adenosine in the central nervous system: A possible role for the A3 adenosine receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann NY Acad Sci. 825:11–22. 1997. View Article : Google Scholar : PubMed/NCBI
39	Borghi-Scoazec G, Scoazec JY, Durand F, Bernuau J, Belghiti J, Feldmann G, Henin D and Degott C: Apoptosis after ischemia-reperfusion in human liver allografts. Liver Transpl Surg. 3:407–415. 1997. View Article : Google Scholar : PubMed/NCBI
40	Zhang BH, Gong DZ and Mei MH: Protection of regenerating liver after partial hepatectomy from carbon tetrachloride hepatotoxicity in rats: Role of hepatic stimulator substance. J Gastroenterol Hepatol. 14:1010–1017. 1999. View Article : Google Scholar : PubMed/NCBI